OBJECTIVES: The aim of the study was to determine the association of coronary computed tomographic angiography (CTA)-identified coronary artery disease (CAD) with post-test aspirin, statin, and antihypertensive medication use and changes in cholesterol and blood pressure (BP). BACKGROUND: The relationship of CTA findings to subsequent changes in preventive cardiovascular medication prescribing patterns and risk factors is largely unknown. METHODS: We studied 1,125 consecutive patients without known CAD referred for coronary CTA. CAD was defined as none, nonobstructive (<50%), or obstructive (≥50%). Prescriptions were queried in the 6 months pre- and post-CTA for comparison of aspirin, statin, and BP treatment. Medication intensification was defined as initiation, dose increase, or, for statins, change to a more potent formulation. Lipid and BP values were obtained at 12 months pre- and post-CTA. RESULTS: Patients were 50 ± 12 years of age (59% men), with 34%, 47%, and 33% on baseline statin, BP medication(s), and aspirin, respectively. Relative to patients without CAD (n = 617), patients with nonobstructive (n = 411) and obstructive CAD (n = 97) demonstrated significant intensification in unadjusted rates of statin (26%, 46%, and 46% of patients; p < 0.001), BP (11%, 21%, and 24%; p < 0.001), and aspirin therapies (9%, 29%, and 40%; p < 0.001), and significant improvements in total cholesterol (-6.7, -14.7, and -24.7 mg/dl; p = 0.008), low-density lipoprotein cholesterol (-5.6, -14.1, and -24.6 mg/dl; p = 0.001), systolic (+0.1, -1.4, and -4.9 mm Hg; p = 0.002), and diastolic BP (-0.6, -1.0, and -3.4 mm Hg; p = 0.012), respectively. Adjusted for baseline risk factors and medications, CAD was independently associated with increased aspirin, statin, and BP medication use rates in CTA-identified nonobstructive CAD (odds ratio [OR]: 6.9, 95% confidence interval [CI]: 4.7 to 10.2; OR: 6.6, 95% CI: 3.0 to 14.3; OR: 1.6, 95% CI: 1.1 to 2.2, respectively; p < 0.05), and aspirin and statin use in obstructive CAD (OR: 42.4, 95% CI: 15.8 to 113.9; OR: 30.3, 95% CI: 3.2 to 289.2, respectively; p < 0.05). CONCLUSIONS: CAD presence and severity on CTA are associated with increased use of preventive cardiovascular medications and improvements in cholesterol and BP.
OBJECTIVES: The aim of the study was to determine the association of coronary computed tomographic angiography (CTA)-identified coronary artery disease (CAD) with post-test aspirin, statin, and antihypertensive medication use and changes in cholesterol and blood pressure (BP). BACKGROUND: The relationship of CTA findings to subsequent changes in preventive cardiovascular medication prescribing patterns and risk factors is largely unknown. METHODS: We studied 1,125 consecutive patients without known CAD referred for coronary CTA. CAD was defined as none, nonobstructive (<50%), or obstructive (≥50%). Prescriptions were queried in the 6 months pre- and post-CTA for comparison of aspirin, statin, and BP treatment. Medication intensification was defined as initiation, dose increase, or, for statins, change to a more potent formulation. Lipid and BP values were obtained at 12 months pre- and post-CTA. RESULTS:Patients were 50 ± 12 years of age (59% men), with 34%, 47%, and 33% on baseline statin, BP medication(s), and aspirin, respectively. Relative to patients without CAD (n = 617), patients with nonobstructive (n = 411) and obstructive CAD (n = 97) demonstrated significant intensification in unadjusted rates of statin (26%, 46%, and 46% of patients; p < 0.001), BP (11%, 21%, and 24%; p < 0.001), and aspirin therapies (9%, 29%, and 40%; p < 0.001), and significant improvements in total cholesterol (-6.7, -14.7, and -24.7 mg/dl; p = 0.008), low-density lipoprotein cholesterol (-5.6, -14.1, and -24.6 mg/dl; p = 0.001), systolic (+0.1, -1.4, and -4.9 mm Hg; p = 0.002), and diastolic BP (-0.6, -1.0, and -3.4 mm Hg; p = 0.012), respectively. Adjusted for baseline risk factors and medications, CAD was independently associated with increased aspirin, statin, and BP medication use rates in CTA-identified nonobstructive CAD (odds ratio [OR]: 6.9, 95% confidence interval [CI]: 4.7 to 10.2; OR: 6.6, 95% CI: 3.0 to 14.3; OR: 1.6, 95% CI: 1.1 to 2.2, respectively; p < 0.05), and aspirin and statin use in obstructive CAD (OR: 42.4, 95% CI: 15.8 to 113.9; OR: 30.3, 95% CI: 3.2 to 289.2, respectively; p < 0.05). CONCLUSIONS: CAD presence and severity on CTA are associated with increased use of preventive cardiovascular medications and improvements in cholesterol and BP.
Authors: Amit Pursnani; Christopher L Schlett; Thomas Mayrhofer; Csilla Celeng; Pearl Zakroysky; Fabian Bamberg; John T Nagurney; Quynh A Truong; Udo Hoffmann Journal: J Cardiovasc Comput Tomogr Date: 2015-02-18
Authors: Michael K Cheezum; Prem Srinivas Subramaniyam; Marcio S Bittencourt; Edward A Hulten; Brian B Ghoshhajra; Nishant R Shah; Daniel E Forman; Jon Hainer; Marcia Leavitt; Ram Padmanabhan; Hicham Skali; Sharmila Dorbala; Udo Hoffmann; Suhny Abbara; Marcelo F Di Carli; Henry Gewirtz; Ron Blankstein Journal: Eur Heart J Cardiovasc Imaging Date: 2015-04-20 Impact factor: 6.875
Authors: Hamed Emami; Richard A P Takx; Thomas Mayrhofer; Sumbal Janjua; Jakob Park; Amit Pursnani; Ahmed Tawakol; Michael T Lu; Maros Ferencik; Udo Hoffmann Journal: JACC Cardiovasc Imaging Date: 2017-03-15
Authors: Edward Hulten; Todd C Villines; Michael K Cheezum; Daniel S Berman; Allison Dunning; Stephan Achenbach; Mouaz Al-Mallah; Matthew J Budoff; Filippo Cademartiri; Tracy Q Callister; Hyuk-Jae Chang; Victor Y Cheng; Kavitha Chinnaiyan; Benjamin J W Chow; Ricardo C Cury; Augustin Delago; Gudrun Feuchtner; Martin Hadamitzky; Jörg Hausleiter; Philipp A Kaufmann; Yong-Jin Kim; Jonathon Leipsic; Fay Y Lin; Erica Maffei; Fabian Plank; Gilbert L Raff; Leslee J Shaw; James K Min Journal: J Nucl Cardiol Date: 2014-01-03 Impact factor: 5.952
Authors: Michael C Honigberg; Bradley S Lander; Vinit Baliyan; Maeve Jones-O'Connor; Emma W Healy; Jan-Erik Scholtz; John T Nagurney; Udo Hoffmann; Brian B Ghoshhajra; Pradeep Natarajan Journal: JACC Cardiovasc Imaging Date: 2019-07-17
Authors: S Divakaran; M K Cheezum; E A Hulten; M S Bittencourt; M G Silverman; K Nasir; R Blankstein Journal: Br J Radiol Date: 2014-12-12 Impact factor: 3.039
Authors: Dan K Kalra; Ran Heo; Valentina Valenti; Ryo Nakazato; James K Min Journal: Arterioscler Thromb Vasc Biol Date: 2014-04-10 Impact factor: 8.311